GSK advances oncology efforts with $10.6bn Nuvalent acquisition
Multi-product oncology deal accelerates GSK’s entry into lung cancer.
GSK is acquiring US biopharma company Nuvalent for $10.6 billion, through which it will gain access to three potential best-in-class assets in lung cancer.
The agreement could lead to significant new treatment options, subject to regulatory approval.
It is the second major oncology deal announced by a pharmaceutical company in several weeks. Pfizer has agreed to…
Already a member? Sign-in
